ICD-10 Code D70.2 | Other drug-induced agranulocytosis Symptoms, Diagnosis, Billing

Other drug-induced agranulocytosis is a serious hematological condition characterized by a significant reduction in neutrophil count due to the adverse effects of certain medications. This condition is clinically important as it increases the risk of severe infections and necessitates prompt medical intervention. The ICD-10 Code D70.2 facilitates accurate diagnosis, documentation, medical billing, and public health reporting, ensuring that healthcare providers can effectively manage and track this potentially life-threatening condition.

What is ICD-10 Code D70.2 for Other drug-induced agranulocytosis?

ICD-10 Code D70.2 represents Other drug-induced agranulocytosis, a condition where the bone marrow fails to produce adequate neutrophils due to the influence of specific drugs. This code should be used in clinical documentation and billing when a patient presents with neutropenia linked to drug exposure, ensuring proper identification of the underlying cause for treatment and management.

ICD-10 Code D70.2 – Clinical Definition and Explanation of Other drug-induced agranulocytosis

Other drug-induced agranulocytosis is primarily caused by the administration of certain medications that can lead to bone marrow suppression. This condition can progress rapidly, resulting in increased susceptibility to infections, which requires immediate medical attention.

Key Clinical Features:

• Severe neutropenia (absolute neutrophil count < 500 cells/mm³)
• Increased risk of opportunistic infections
• Symptoms may include fever, chills, and sore throat
• History of recent medication use associated with agranulocytosis

ICD-10 Code D70.2 for Other drug-induced agranulocytosis – SOAP Notes & Clinical Use

In SOAP notes, ICD-10 Code D70.2 is utilized to document the patient's symptoms, assessment findings, and treatment plans related to drug-induced agranulocytosis. This code is relevant in both acute and chronic care settings, ensuring comprehensive documentation of the patient's condition and facilitating appropriate management.

What Does ICD-10 Code D70.2 for Other drug-induced agranulocytosis Mean in SOAP Notes?

ICD-10 Code D70.2 connects subjective patient-reported symptoms and objective clinical findings to a formal diagnosis of drug-induced agranulocytosis. This code is essential for ensuring continuity of care, supporting accurate billing, and meeting EHR documentation standards.

Treatment Options for ICD-10 Code D70.2 – Other drug-induced agranulocytosis

The management of Other drug-induced agranulocytosis often requires hospitalization due to the risk of severe infections. Treatment may include specific antibiotic therapy and supportive care.

Antibiotic Therapy:

• First-line: Broad-spectrum antibiotics such as piperacillin-tazobactam or cefepime for 7-14 days
• Alternative: Carbapenems or vancomycin if MRSA is suspected
• Duration: Tailored based on clinical response and culture results

Supportive Care:

• Monitor vital signs and laboratory parameters closely
• Administer granulocyte colony-stimulating factor (G-CSF) if indicated
• Provide hydration and nutritional support as needed

Infection Control:

• Implement strict hand hygiene protocols
• Use isolation precautions for patients with neutropenia
• Educate patients and caregivers on infection prevention strategies

How to Document Symptoms of Other drug-induced agranulocytosis (ICD-10 D70.2) in SOAP Notes

Subjective:

• Patient reports fever and chills over the past 48 hours
• History of recent medication use, including antipsychotics and antibiotics
• Complaints of sore throat and fatigue
• No known allergies reported

Objective:

• Vital signs: Temperature 101°F, heart rate 110 bpm
• Laboratory findings: Absolute neutrophil count of 300 cells/mm³
• Physical exam: Oral mucosa shows signs of ulceration
• No lymphadenopathy noted on examination

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more

SOAP Note Guidelines for Diagnosing Other drug-induced agranulocytosis (ICD-10 Code D70.2)

Assessment:

• Diagnosis: Other drug-induced agranulocytosis, severe (ICD-10 D70.2)
• Severity: Classified as severe due to neutrophil count < 500 cells/mm³
• Contributing factors: Recent use of medications known to cause agranulocytosis
• Monitor for potential complications such as sepsis

Plan:

• Initiate broad-spectrum intravenous antibiotics
• Consider G-CSF therapy to stimulate neutrophil production
• Educate patient on signs of infection and when to seek immediate care
• Schedule follow-up CBC in 48 hours to monitor response

Treatment & Plan Section for ICD-10 Code D70.2 – Other drug-induced agranulocytosis

• Administer appropriate antibiotics based on culture results and clinical judgment
• Implement infection control measures to prevent complications
• Provide patient education on recognizing symptoms of infection
• Schedule regular follow-up appointments to monitor blood counts

Using ICD-10 Code D70.2 for Other drug-induced agranulocytosis in Billing & SOAP Note Compliance

• Ensure accurate documentation of symptoms and medication history in Subjective (S) and Objective (O) sections
• Use D70.2 in conjunction with relevant procedure codes for billing
• Document treatment plans that align with clinical guidelines to support justified billing
• Review coding updates regularly to maintain compliance with payer requirements

Related ICD-10 Codes Often Used with Other drug-induced agranulocytosis

• D70.1 – Autoimmune agranulocytosis
• D70.0 – Congenital agranulocytosis
• D70.3 – Agranulocytosis due to other specified causes

ICD-10 Code D70.2 in Medical Billing and Insurance for Other drug-induced agranulocytosis

ICD-10 Code D70.2 is critical in medical billing, particularly in hospital, ER, or infectious disease care settings.

Billing Notes:

• Document all relevant clinical findings and treatment details to support the claim for D70.2.
• Use this code in acute care settings where immediate intervention is required.
• Ensure that the patient's medication history is clearly documented to justify the diagnosis.
• Review payer-specific guidelines for coding and billing to avoid denials.

Common CPT Pairings: